Full Fed. Circ. Won't Revive Juno's $1.2B Cancer Patent Win
By Dani Kass · January 14, 2022, 7:34 PM EST
The full Federal Circuit said Friday that it will not review a panel decision wiping out Bristol-Myers Squibb subsidiary Juno Therapeutics' $1.2 billion patent infringement victory against Gilead's Kite Pharma Inc....
To view the full article, register now.